SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. Co. is focused on the development of novel therapeutics for a range of cancer indications. Co.'s product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. We show 28 historical shares outstanding datapoints in our SLS shares outstanding history coverage, used to compute SLS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SLS market cap history over the course of time is important for investors
interested in comparing SLS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SLS versus a peer is one thing; comparing
SLS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SLS can fluctuate over the course of history.
With this page we aim to empower investors researching SLS by allowing them to research the SLS market cap history. |
Free SLS Email Alerts:
Video: The Importance of Market Cap
